07:46 AM EDT, 09/15/2025 (MT Newswires) -- NovoCure ( NVCR ) said Monday that Japan's Ministry of Health, Labour and Welfare has approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors to treat certain adult patients with non-small cell lung cancer.

Optune Lua is a wearable, portable medical device that produces alternating electric fields that kill cancer cells, the company said.

The approval was based on results from the phase 3 LUNAR trial that compared the use of Optune Lua with PD-1/PD-L1 inhibitors to PD-1/PD-L1 inhibitors alone for non-small cell lung cancer patients who progressed during or after platinum-based chemotherapy.

The company said that the study achieved its primary endpoint with a statistically significant and clinically meaningful 3.3-month extension in median overall survival for patients treated with Optune Lua with a PD-1/PD-L1 inhibitor.